Refine
Has Fulltext
- yes (302)
Is part of the Bibliography
- yes (302)
Year of publication
Document Type
- Journal article (228)
- Doctoral Thesis (51)
- Book article / Book chapter (14)
- Conference Proceeding (6)
- Review (2)
- Preprint (1)
Language
- English (302) (remove)
Keywords
- Toxikologie (119)
- DNA damage (15)
- Adenosine receptors (9)
- Adenosinrezeptor (8)
- Genotoxicity (7)
- oxidative stress (7)
- DNS-Schädigung (6)
- GPCR (6)
- Micronuclei (6)
- DNA (5)
- DNA binding (5)
- G-Protein gekoppelte Rezeptoren (5)
- Pharmakologie (5)
- Adenylate cyclase (4)
- FRET (4)
- Fluoreszenz-Resonanz-Energie-Transfer (4)
- G proteins (4)
- Medizin (4)
- Oxidativer Stress (4)
- heart failure (4)
- metabolism (4)
- micronuclei (4)
- mycotoxin (4)
- vitamin B6 (4)
- 1 (3)
- Biotransformation (3)
- Carcinogen (3)
- Carcinogenesis (3)
- Carcinogenicity (3)
- Carcinogens (3)
- DNA-Schaden (3)
- ERK1/2 (3)
- Enzyme induction (3)
- Ernährung (3)
- G protein-coupled receptors (3)
- Genotoxizität (3)
- Kleinkern (3)
- Mutagenität (3)
- Pneumolysin (3)
- apoptosis (3)
- cAMP (3)
- cardiac hypertrophy (3)
- cytoskeleton (3)
- fluorescence resonance energy transfer (3)
- genotoxicity (3)
- inflammation (3)
- liver (3)
- nephrotoxicity (3)
- signal transduction (3)
- transcription factors (3)
- 18F-FDG (2)
- 5-Azacytidine (2)
- A1 adenosine receptors (2)
- Adenosin (2)
- Adrenerger Rezeptor (2)
- Aldosteron (2)
- Ames test (2)
- Angiotensin II (2)
- Bakteriengift (2)
- Benzene (2)
- Carcinogenität (2)
- DNA Binding (2)
- DNA Schaden (2)
- DNA repair (2)
- Diethylstilbestrol (2)
- Dose response (2)
- Dose-response relationship (2)
- Electropermeabilization (2)
- Estrogen (2)
- FCS (2)
- Förster Resonanz Energie Transfer (2)
- G-Protein gekoppelter Rezeptor (2)
- G-protein (2)
- HPLC-MS (2)
- Herzhypertrophie (2)
- Hirnhautentzündung (2)
- Hormone (2)
- In vitro (2)
- Inhalation (2)
- Insulin (2)
- Leber (2)
- Meningitis (2)
- Metabolic activation (2)
- Micronucleus (2)
- Muscarinrezeptor (2)
- Myokarditis (2)
- N-formyl peptides (2)
- Niere (2)
- PET (2)
- Pharmakokinetik (2)
- Pharmazie (2)
- QIVIVE (2)
- RKIP (2)
- Radioligand binding (2)
- Rat (2)
- Reproductive toxicity (2)
- Risk Assessment (2)
- Salmonella/microsome assay (2)
- Silicones (2)
- Toxicology (2)
- Toxin (2)
- actin (2)
- actinomycetes (2)
- adenosine receptors (2)
- aldosterone (2)
- barbiturates (2)
- biased signaling (2)
- binding (2)
- biomedicine, general (2)
- cGMP (2)
- calcium (2)
- cancer (2)
- cancer risk (2)
- carcinogen (2)
- carcinogenicity (2)
- cell biology (2)
- comet assay (2)
- cytokinins (2)
- dialysis (2)
- differentiation (2)
- environmental health (2)
- familial DCM (2)
- fluorescence (2)
- fluorescence imaging (2)
- genomic damage (2)
- heart (2)
- iPSC-cardiomyocytes (2)
- immunohistochemistry (2)
- in-vivo (2)
- insulin (2)
- kidneys (2)
- lymphocytes (2)
- mast cells (2)
- medicine (2)
- membrane skeleton (2)
- meningitis (2)
- mercapturic acid (2)
- mutagenicity (2)
- myocarditis (2)
- occupational medicine/industrial medicine (2)
- pharmacogenetics (2)
- pharmacokinetics (2)
- pharmacology/toxicology (2)
- phosphorylation (2)
- pneumolysin (2)
- positron emission tomography (2)
- pyridoxal phosphatase (2)
- rat brain membranes (2)
- receptors (2)
- resveratrol (2)
- risk assessment (2)
- therapy (2)
- toxicity (2)
- uremic toxins (2)
- yam (2)
- (Mouse L-cell) (1)
- (Rat brain membrane) (1)
- (Rat liver) (1)
- (Salmonella) (1)
- 1H-NMR-Spectroscopy (1)
- 2 (1)
- 2',7'-dichlorofluorescin (1)
- 2-Acetylaminofluorene (1)
- 2-Dichloroethane (1)
- 2-Dioxetane (1)
- 2-Generation reproduction (1)
- 2-acetylaminofluorene (1)
- 3 (1)
- 3-pentafluoropropene (1)
- 3-tetrafluoropropene (1)
- 3R (1)
- 4'-hydroxylation (1)
- 4-(p-nitrobenzyl)pyridine (1)
- 6-benzylaminopurine (1)
- 7,8-dihydroxyflavone (7,8-DHF) (1)
- 8-Hydroxy-deoxyguanosine (1)
- A(2B) receptors (1)
- A1 (1)
- A1 Adenosine receptors (1)
- A2B adenosine receptor (1)
- A2BAR (1)
- A<sub>2</sub> Adenosine receptor (1)
- AMPK (1)
- API-Massenspektrometrie (1)
- AUM (1)
- A\(_{2A}\) adenosine receptor antagonist (1)
- Acetylcysteinderivate (1)
- Acrylamid (1)
- Acrylamide (1)
- Actin (1)
- Actin cytoskeleton (1)
- Adenosine receptor (1)
- Adenosine receptor antagonists (1)
- Adrenergic receptor (1)
- Adverse outcome pathway (AOP) (1)
- Aflatoxin (1)
- Aflatoxin B1 (1)
- Aldosteronantagonist (1)
- Alkylation (1)
- Alzheimers disease (1)
- Amino acid composition (1)
- Amino acids (1)
- Aminosäuren (1)
- Anabolieagent (1)
- Angiotensin-II-Blocker (1)
- Angst (1)
- Aniline derivatives (1)
- Animal model (1)
- Anthocyane (1)
- Anthraquinone glycosides (1)
- Antibodies (1)
- Antikörper (1)
- Anxiety (1)
- Apoptose (1)
- Apoptosis (1)
- Aryl hydrocarbon rnonooxygenase (1)
- Astrozyt (1)
- Atria (1)
- Aufmerksamkeits-Defizit-Syndrom (1)
- Autofocus (1)
- Azole (1)
- Azoles (1)
- B cells (1)
- BETA(2)-adrenergic receptor (1)
- BRET (1)
- Background DNA damage (1)
- Bacterial Toxins (1)
- Bacterial meningitis (1)
- Bakterielle Hirnhautentzündung (1)
- Bakterien (1)
- Barbiturat (1)
- Barbiturates (1)
- Barth syndrome (1)
- Bcl-2 (1)
- Benfotiamin (1)
- Benzefuran dioxetane (1)
- Benzefuran epoxide (1)
- Benzo(a)pyrene-DNA binding (1)
- Berenil (1)
- Beta(1)-adrenergic receptor (1)
- Beta(2)-adrenergic receptor (1)
- Beta-1-Rezeptor (1)
- Beta-1-receptor (1)
- Beta-Adrenergic Receptor (1)
- Beta-Adrenozeptor (1)
- Bioluminescence resonance energy transfer (1)
- Biomarker (1)
- Biomarkers (1)
- Biosensor (1)
- Bisphenol A (1)
- Bromodeoxyuridine labeling (1)
- Brustkrebs (1)
- C1q/TNF related protein (CTRP) (1)
- CAMP production (1)
- CFC replacements (1)
- CIB1 (1)
- CRISPR Cas9 (1)
- CRISPR/Cas9 (1)
- CXCR4 (1)
- CYP19 (1)
- CYP51 (1)
- CaMKII (1)
- Calcium (1)
- Cancer prevention (1)
- Carcinogen risk Individual susceptibili (1)
- Carcinogenic potency (1)
- Cardiac myocyte ; Beta-Receptor ; Muscarinic receptor ; cAMP ; G-protein ; Serum (1)
- Cardiomyocyte (1)
- Cell adhesion (1)
- Cell death and comet assay (1)
- Cell transformation (1)
- Chemical carcinogenesis (1)
- Chemokine (1)
- Chemokine receptors (1)
- Chemotactic receptors (1)
- Chlorfluorkohlenstoffe (1)
- Choline deficiency (1)
- Cholinesteraseinhibitor (1)
- Chromosome aberration (1)
- Chromosome distribution (1)
- Chronic heart-failure (1)
- Clonidin (1)
- Co-culture (1)
- Colon cancer (1)
- Comet Assay (1)
- Comet assay (1)
- Covalent DNA binding (1)
- Covalent binding (1)
- Covalent binding index (1)
- Covalent binding index - Diethylstilbestrol (1)
- Cyclic AMP (1)
- Cyclo-AMP (1)
- Cyclo-GMP (1)
- Cytochrom P450 (1)
- Cytochrome b5 (1)
- Cytologie (1)
- DAMGO (1)
- DCM genetic background (1)
- DES (1)
- DNA Damage (1)
- DNA adduct . Repair endonuclease (1)
- DNA adducts (1)
- DNA binching (1)
- DNA crosslink (1)
- DNA damage response (1)
- DNA metabolism (1)
- DNA methylation (1)
- DNA transfection (1)
- DNA-Addukte (1)
- DNA-Vernetzung (1)
- DNS-Bindung (1)
- DNS-Strangbruch (1)
- Depression (1)
- Dermatologie (1)
- Di (1)
- Dietary process-related contaminants (1)
- Diisononyl phthalate (1)
- Dilated cardiomyopathy (1)
- Dioscorea (1)
- Dose response relationships (1)
- Dosis-Wirkungs-Beziehung (1)
- Drug resistance (1)
- Dualstere Liganden (1)
- Dualsteric Ligands (1)
- ERK signaling (1)
- ERK-Kaskade (1)
- ERK-cascade (1)
- Electric Field (1)
- Electrical breakdown (1)
- Electrophiles (1)
- Elektrofusion (1)
- Elektroporation (1)
- Emodin (1)
- Endogenous genotoxicity (1)
- Entzündung (1)
- Epoxide hydrolase (1)
- Erk1/2 (1)
- Ersatzstoff (1)
- Estrone (1)
- Ethionine (1)
- Eukaryotic cell (1)
- Excitotoxicity (1)
- External exposure assessment (1)
- Extrakorporale Dialyse (1)
- FCKW-Ersatzstoffe (1)
- FPG protein (1)
- FRET sensors (1)
- Fabry Disease (FD) (1)
- Fischer 344 rats (1)
- Flow cytometry (1)
- Fluorescence (1)
- Fluorescence Correlation Spectroscopy (1)
- Fluorescence Microscopy (1)
- Fluorescence resonance energy transfer (1)
- Fluorescence-resonance-energy-transfer (1)
- Fluoreszenz (1)
- Fluoreszenzkorrelationsspektroskopie (1)
- Fluoreszenzmikroskopie (1)
- Fluorkohlenwasserstoffe (1)
- Fluoxetin (1)
- Fluoxetine (1)
- Friedreich’s ataxia (1)
- Fumonisin B1 (1)
- Fumonisine (1)
- Fungizid (1)
- Furan (1)
- Förster Resonance Energy Transfer (1)
- G Protein-Coupled Receptor (1)
- G protein coupled receptor (1)
- G protein coupled receptor (GPCR) (1)
- G protein-coupled receptor (1)
- G protein-coupled receptor kinase (1)
- G-protein coupled receptor (1)
- G-protein-coupled receptors (1)
- GABA-receptor complex (1)
- GC-MS (1)
- GC/MS (1)
- GFAT1 (1)
- GFAT2 (1)
- GFPT1 (1)
- GFPT2 (1)
- GPCR dimerisation (1)
- GPCR signaling (1)
- GPCRs (1)
- GTP-bindende Proteine (1)
- Gastric carcinogenesis (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- Gene Transfer (1)
- Gene transfer (1)
- Genetic instability (1)
- Genomschaden (1)
- Genotyp (1)
- Gentoxikologie (1)
- Glutathion S-Konjugat (1)
- Glutathione Stransferase (1)
- Guanin Nukleotid Austauschfaktor (1)
- Guaninnucleotid-Austauschfaktoren (1)
- Guanylatcyclase (1)
- HCN channel (1)
- HCN-Kanal (1)
- HFC245fa (1)
- HIV (1)
- HIV infection (1)
- HPLC-MS/MS method (1)
- HeLa H2B-GFP cells (1)
- HeLa H2B-GFP-Zellen (1)
- HeLa cells (1)
- Heart failure (1)
- Hemmung der Proliferation schnell wachsender Krebszellen (1)
- HepG2 cells (1)
- HepG2-Zellen (1)
- Herpesviren (1)
- High-thropughput screening (1)
- High-throughput screening (1)
- Hintergrund-DNA-Schaden (1)
- Hochdurchsatz-Screening (1)
- Hoechst 33258 dye (1)
- Homocystein (1)
- Hsp90 (1)
- Human platelets (1)
- Hybridoma (1)
- Häm (1)
- I1 Imidazolin Bindungsstelle (1)
- I1 imidazoline binding site (1)
- Immunization (1)
- Immunologie (1)
- In vitro testing (1)
- In vitro toxicity testing (1)
- In vivo (1)
- In-silico Modell (1)
- Inflammation (1)
- Inhibition (1)
- Ischemia/reperfusion (1)
- Jolly bodies (1)
- K + -channels (1)
- Kanzerogenese (1)
- Kardiomyozyt (1)
- Kidneys (1)
- Kinetochore (1)
- Kinetochores (1)
- Knockout (1)
- Kongestive Herzmuskelkrankheit (1)
- Krebs (1)
- Krebs <Medizin> (1)
- L5178Y cells (1)
- LC-MS (1)
- LC-MS/MS (1)
- LTB4 receptor (1)
- Latrophilin (1)
- Leukocyte/endothelium interaction (1)
- Ligand <Biochemie> (1)
- Lung (1)
- MAP-Kinase (1)
- MMQ cells (1)
- Magenkrebs (1)
- MammaJian mutagenicity test (1)
- Massenspektrometrie (1)
- Mastzelle (1)
- Maus (1)
- Mechanism of action (1)
- Melanocortin 4 receptor (MC4R) (1)
- Melanocyte stimulating hormones MSH (1)
- Membrane transporters (1)
- Membrantransporter (1)
- Merkaptolaktat (1)
- Merkaptursäure (1)
- Merkaptursäuren (1)
- Metabolic enzymes (1)
- Metabolism (1)
- Metabolism saturation (1)
- Metabolismus (1)
- Metabonomics (1)
- Metabonomix (1)
- Methylphenidat (1)
- Microcirculation (1)
- Micronucleus formation (1)
- Micronucleus test (1)
- Microscopy (1)
- Mikrokerne (1)
- Mitosis (1)
- Mitotic disturbance (1)
- Molekularpharmakologie (1)
- Multivariate Analyse (1)
- Mutagenicity (1)
- Mutagenicity assay (1)
- Mutagenitätstest (1)
- Mutagens (1)
- Mutation assay (1)
- Mykotoxin (1)
- N-methyl-N-nitrosourea (1)
- N1E 115 cells (1)
- NADPH-Oxidase (1)
- Na\(_V\)1.8 (1)
- Neomycin Resistance (1)
- Nephrotoxicity (1)
- Nephrotoxizität (1)
- Nervennetz (1)
- Nervenzelle (1)
- Nitrosation (1)
- Nitrosativer Stress (1)
- Nitrosierung (1)
- O-GlcNAc (1)
- OXPHOS (1)
- Oxidative Stress (1)
- Oxidative stress (1)
- Oxygen radical (1)
- PBPK/PBTK model (1)
- PDE (1)
- PDE2 (1)
- PDXP inhibitors (1)
- PKA (1)
- PTH1R (1)
- Parathormon (1)
- Partial Agonists (1)
- Partialagonismus (1)
- Patulin (1)
- Peptides (1)
- Perforine (1)
- PhD thesis pharmacology (1)
- Pharmakogenetik (1)
- Phosphatase (1)
- Phosphatasen (1)
- Phosphodiesterase (1)
- Phosphoglykolat-Phosphatase (1)
- Phosphoglykolatphosphatase (1)
- Photoaffinity labelling (1)
- Physiologically based kinetic models (1)
- Physiologie (1)
- Phänotyp (1)
- Pointmutation (1)
- Pore (1)
- Pore formation (1)
- Pore-formation (1)
- Porenbildung (1)
- Prevalence (1)
- Prognostic impact (1)
- Prolactin (1)
- Propenderivate (1)
- Protein binding (1)
- Protein coding (1)
- Proteinaddukte (1)
- Proteinbindung (1)
- Proteintyrosinphosphatase (1)
- Protonen-NMR-Spektroskopie (1)
- Pyrrolizidinalkaloide (1)
- Pyrrolizidine alkaloids (1)
- Quantitative risk assessment (1)
- RAMP (1)
- RBM20 mutations (1)
- ROS (1)
- Radiation inactivation (1)
- Radicals (1)
- Radioligand binding - 86Rb + -efflux (1)
- Radioligands (1)
- Radioligauds (1)
- Raf kinase inhibitor protein (1)
- Raman micro-spectroscopy (1)
- Rat Iiver microsomes (1)
- Rat liver peroxisome (1)
- Ratte (1)
- Reactive intermediates (1)
- Reaktive Zwischenstufe (1)
- Receptor (1)
- Receptor dynamics (1)
- Regulation (1)
- Regulator of G protein signaling 2 (1)
- Renin-Angiotensin-System (1)
- Resveratrol (1)
- Rgs2 (1)
- Riot control agents (1)
- Risikoanalyse (1)
- Risikobewertung (1)
- Risk assessment (1)
- Risk estimation (1)
- Risk-factors (1)
- SCN5a (1)
- ST-elevation myocardial infarction (1)
- Salmonella typhimurium (1)
- Sensitivity (1)
- Sensor (1)
- Short-term tests (1)
- Signal transduction (1)
- Species Differences (1)
- Species differences (1)
- Spermatogenesis (1)
- Speziesunterschiede (1)
- Spontaneous tumours (1)
- Src (1)
- Stable Transformation (1)
- Statin (1)
- Stickstoffoxidsynthase (1)
- Streptococcus pneumoniae (1)
- Streptomyces (1)
- Stress (1)
- Structureactivity relationship (1)
- Styrol (1)
- Systembiologie (1)
- T cells (1)
- TK6 cells (1)
- Target size (1)
- Theophylline (1)
- Thymidine glycol (1)
- Tiermodell (1)
- Toxicokinetics (1)
- Toxikokinetik (1)
- Toxizität (1)
- Toxizitätstest (1)
- Transfection (1)
- Transgenic mouse (1)
- Transgenie mice (1)
- Transkriptionsfaktoren (1)
- Trenbolone (1)
- Trifluorpropionsäure (1)
- Tumorzelle (1)
- Tyrosin (1)
- Tyrosin phosphatase (1)
- Unscheduled DNA synthesis (1)
- Urämische Toxine (1)
- Uterine tumors (1)
- Valvular heart-desease (1)
- Venerologie (1)
- Volume distribution (1)
- Wachstumskonus (1)
- Water resources (1)
- Xanthines (1)
- Zell-Adhäsion (1)
- Zelladhäsion (1)
- Zelle (1)
- Zellkultur (1)
- Zellskelett (1)
- Zellteilung (1)
- Zelltransport (1)
- [3H]PIA binding (1)
- absorption (1)
- actin cytoskeleton (1)
- activation (1)
- active zone (1)
- acute slices (1)
- adduct (1)
- adenine (1)
- adenosine (1)
- adenosine 3',5'-cyclic monophosphate (1)
- adenylate cyclase (1)
- adenylyl cyclase signaling cascade (1)
- adenylyl-cyclase isoforms (1)
- adhesion GPCR (1)
- adiponectin (1)
- adipose tissue (1)
- adrenerge Rezeptoren (1)
- adrenergic receptors (1)
- adult cardiac myocytes (1)
- adverse outcome pathway (1)
- adverse outcome pathway (AOP) (1)
- aflatoxin (1)
- aflatoxin B1 (1)
- ageing (1)
- agonists (1)
- alkylation (1)
- allelic variant (1)
- alpha2-KO Maus (1)
- alpha2-KO mouse (1)
- alpha2-Rezeptor (1)
- alpha2-receptor (1)
- alternative methods (1)
- amine (1)
- amino acid (1)
- antagonists (1)
- anthocyanins (1)
- anti-Parkinson agents (1)
- anti-inflammatory agents (1)
- antibacterial/antiviral drug (1)
- antibodies (1)
- antibody/autoantibody (1)
- antioxidants (1)
- aortocaval fistula model (1)
- aromatic amides (1)
- arrhythmia (1)
- arrhythmogenesis (1)
- assay (1)
- association (1)
- astrocytes (1)
- atopic eczema (1)
- atrial natriuretic peptide (1)
- avaliação de risco (1)
- bacterial meningitis (1)
- bariatric surgery (1)
- base excision repair (incision activity) (1)
- beta2-adrenoceptor knockout (1)
- beta3 CL 316,243 (1)
- binding affinity (1)
- bioactive compounds (1)
- biofilms (1)
- biological techniques (1)
- biology (1)
- biomarker (1)
- biomarker of exposure (1)
- biomarkers (1)
- biotransformation (1)
- bisphenol a (1)
- blood coagulation factor XIII (1)
- blood plasma (1)
- blood pressure (1)
- blood samples (1)
- bone marrow (1)
- brain damage (1)
- brain membranes (1)
- calcitonin gene-related peptide (1)
- calmodulin (1)
- cardiac magnetic resonance imaging (1)
- cardiac myocyte ; muscarinic K current ; G-protein ; Albumin ; serum (1)
- cardiac remodelling (1)
- cardiomyocyte (1)
- cardiomyocytes (1)
- cardiovascular diseases (1)
- caveolin-1 (1)
- cell adhesion (1)
- cell culture (1)
- cell fate (1)
- cell fusion (1)
- cell proliferation (1)
- cell signalling (1)
- cell staining (1)
- cellular-trafficking (1)
- chalcone (1)
- chemotactic receptors (1)
- chemotaxis (1)
- child health (1)
- cholesterol depletion (1)
- cholesterol-dependent cytolysin (1)
- cholinesterase (1)
- cholinesterase inhibitors (1)
- chronic heart failure (1)
- chronic kidney disease (1)
- chronophin (1)
- cisplatin (1)
- classification (1)
- classification and labeling (1)
- clinical genetics (1)
- clonidine (1)
- co-culture (1)
- coated vesicles (1)
- cognitive impairment (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- compartments (1)
- computational biophysics (1)
- conduction disease (1)
- conformational auto-epitope (1)
- conjugated mycotoxins (1)
- constitutive activity (1)
- contact lens (1)
- continuous (1)
- contractility (1)
- coumarin (1)
- coupled (1)
- coupled receptor (1)
- covalent (1)
- covalent binding (1)
- creatinine (1)
- crystal structure (1)
- cyclic AMP (1)
- cyclic dipeptide (1)
- cyclic nucleotides such as cyclic adenosine monophosphate (1)
- cyclic peptides/cyclopeptides (1)
- cyclic-AMP (1)
- cyclic-gmp (1)
- cyclopeptide therapy (1)
- cytochrome P450 2C9 (1)
- cytochrome P450s (1)
- cytochrome p450 (1)
- cytogenetic effects (1)
- cytome biomarkers (1)
- cytosol (1)
- cytotoxic (1)
- dCIRL (1)
- danio rerio (1)
- definition (1)
- dendritic spines (1)
- desensitization (1)
- detrusor muscle (1)
- developmental biology (1)
- diabetes (1)
- diagnosis (1)
- dicyclohexyl phthalate (1)
- diet (1)
- dilated cardiomyopathy with ataxia (1)
- disrupting chemicals (1)
- disruptor endócrino (1)
- docking (1)
- domains (1)
- dormancy (1)
- dose (1)
- down-regulation (1)
- drug (1)
- dualsteric ligands (1)
- dunce (1)
- eccentric hypertrophy (1)
- ectodomain cleavage (1)
- efficient intervention points (1)
- endocrine disruptor (1)
- endogenous (1)
- energy-transfer (1)
- environmental phenols (1)
- enzyme-linked immunoassays (1)
- epigenetics (1)
- estrogen receptor (1)
- ethanol (1)
- etoposide (1)
- etox database (1)
- eugenol (1)
- exposição humana (1)
- exposure (1)
- extrapolation (1)
- fatty liver (1)
- fentanyl (1)
- fetal testis (1)
- fluorescence correlation spectroscopy (1)
- fluorescence detection (1)
- fluorescence recovery after photobleaching (1)
- fluorescent probes (1)
- fluorocarbons (1)
- food contact materials (1)
- food safety (1)
- food security (1)
- formyl peptides (1)
- fumonisin B1 (1)
- functional clustering (1)
- fungi (1)
- furan (1)
- gastrointestinal cancer (1)
- general medicine (1)
- genetics (1)
- genotoxic (1)
- genotypes (1)
- genotyping (1)
- glucuronide (1)
- glutamate (1)
- glutathion S-conjugate (1)
- glycolytic flux control (1)
- gprotein (1)
- gravidez (1)
- growth cone (1)
- guanine nucleotide exchange factor (1)
- hA<sub>3</sub>AR (1)
- hOCT1 (1)
- haematopoietic stem cells (1)
- halo olefines (1)
- haloacid dehalogenase (1)
- haloacid dehalogenase-type phosphatase (1)
- healing and remodelling processes (1)
- heme (1)
- heterogeneous population (1)
- hexosamine biosynthesis pathway (1)
- hiPSC-CM (1)
- hidden mycotoxins (1)
- histamine release (1)
- homeostasis (1)
- homocysteine (1)
- homodimerization (1)
- hormone receptors (1)
- human (1)
- human A(3) (1)
- human biomonitoring (1)
- human exposure (1)
- human lung (1)
- hydrofluorocarbons (1)
- hypertension (1)
- hypertonic solution (1)
- identification (1)
- image analysis (1)
- impact pharmacogenetics (1)
- in vitro (1)
- in vivo (1)
- in-silico model (1)
- individual (1)
- indolylpyrimidylpiperazines (1)
- induced pluripotent stem cell cardiomyocytes (1)
- induced pluripotent stem cells (1)
- induzierte Phosphatasen MKP-1 und MKP-2 (1)
- inflammatory diseases (1)
- inhalation (1)
- inhibitors (1)
- insulin signaling (1)
- internalization (1)
- international union (1)
- intracellular calcium release (1)
- intracellular loop (1)
- intrinsic metabolism (1)
- ionic look (1)
- ischemic stroke (1)
- isoproterenol (1)
- key event relationship (1)
- kidney (1)
- kinases (1)
- laminopathy (1)
- lamivudine (1)
- late Na\(^+\) current (I\(_{NaL}\)) (1)
- legislation (1)
- life (1)
- ligand binding (1)
- lipid rafts (1)
- lipidomics (1)
- listeriolysin O (1)
- live imaging (1)
- liver microsomes (1)
- living vells (1)
- long-read sequencing (1)
- lovastatin (1)
- lysosomal disruption (1)
- lysosomal storage disorders (1)
- lösliche Guanylylcyclase (1)
- mTOR-inhibitor RAD-001 (1)
- maintenance of genomic integrity (1)
- major depression (1)
- male rats (1)
- mammalian genomics (1)
- marine sponges (1)
- masked mycotoxins (1)
- mass spectrometry (1)
- matrix metalloproteinase (1)
- maturation strategies (1)
- mechanotransduction (1)
- membrane (1)
- membrane transporters (1)
- memory B cells (1)
- mercaptolactic acid (1)
- mercapturic acids (1)
- metabolische Aktivierung (1)
- metabolische Enzyme (1)
- metabolites (1)
- metabonomics (1)
- metabotropic signalling (1)
- micronucleus (1)
- micronucleus assay (1)
- micronucleus test (1)
- microvessel permeability (1)
- mild (1)
- mitochondria (1)
- mitochondrial DNA polymerase γ (1)
- mitochondrial cardiomyopathy (1)
- mitotic disturbance (1)
- mitotische Störung (1)
- modelo PBPK/PBTK (1)
- modified mycotoxins (1)
- molecular biology (1)
- molecular dynamics (1)
- molecular modeling (1)
- molecular modelling (1)
- monogenetic cardiomyopathies (1)
- mortality (1)
- motor performance (1)
- mouse lymphoma L5178Y (1)
- mouse models DNA damage (1)
- mucosa (1)
- multivariate analysis (1)
- multivariate data analysis (1)
- muscarinic acetylcholine receptor (1)
- mutagen (1)
- mutant mice (1)
- mutation triggers (1)
- mycotoxin derivates (1)
- mycotoxin metabolites (1)
- mycotoxins (1)
- n-hexyl phthalate (1)
- nanopore (1)
- natural (1)
- neocortex (1)
- neurodegenerative diseases (1)
- neuronal dendrites (1)
- neurons (1)
- neuropsychiatric diseases (1)
- neurotransmitter biosynthesis (1)
- neutrophils (1)
- nitric-oxide (1)
- nitrosation (1)
- nitrosative stress (1)
- nitroso compound (1)
- no (1)
- nutritional composition (1)
- o-Chlorobenzylidene malononitrile (1)
- obesity (1)
- occurrence (1)
- ochratoxin A (1)
- octopamine (1)
- oligomerization (1)
- opioid ligands (1)
- opioid receptor (1)
- optimal drug combination (1)
- optimal drug targeting (1)
- optimal pharmacological modulation (1)
- optimal treatment strategies (1)
- organ toxicity (1)
- oxidativer Stress (1)
- p53 (1)
- parathyroid hormone (1)
- parathyroid hormone 1 receptor (1)
- partial agonists (1)
- performance liquid-chromatography (1)
- peripheral nerve (1)
- peripheral-blood lymphocytes (1)
- personalized treatment (1)
- perspectives (1)
- pharmacology (1)
- phenotyping (1)
- phosphoglycolate phosphatase (1)
- phosphoinositides (1)
- photoaffinity labelling (1)
- plasma membrane (1)
- poly(ADP-ribosyl)ation (1)
- pore formation (1)
- pore-forming toxin (1)
- potent (1)
- pregnancy (1)
- primary aromatic amine (1)
- protein (1)
- protein adducts (1)
- protein alkylation (1)
- protein design (1)
- protein-coupled receptors (1)
- protein-coupled-receptors (1)
- psoriasis (1)
- psychiatric disorders (1)
- purine derivatives (1)
- pyridoxal phosphatase (PDXP) (1)
- pyrrolizidine alkaloids (1)
- quantitative assessments (1)
- radiation (1)
- radii (1)
- radioligand (1)
- radioligand binding (1)
- rat pheochromocytoma cells (1)
- rats (1)
- reactive metabolites (1)
- reaktive Metabolite (1)
- receptor binding (1)
- receptor pharmacology (1)
- receptor solubilization (1)
- receptor-G protein coupling (1)
- receptor-G protein coupling. (1)
- reduction of ERK1/2 phosphorylation (1)
- reduction of cells proliferation (1)
- regulation (1)
- relaxation (1)
- renal toxicity (1)
- repeated dose (1)
- reproductive and developmental toxicity (1)
- risk (1)
- risk-assesment (1)
- sensor (1)
- sensory physiology (1)
- serum (1)
- sex (1)
- sexual development (1)
- signaling microdomain (1)
- simulated digestion (1)
- single-molecule imaging (1)
- single-molecule microscopy (1)
- solid-phase extraction (1)
- solubilization (1)
- soluble guanylyl cyclase (1)
- splenic function (1)
- sponges (1)
- spontaneously hypersensitive-rats (1)
- staphilococci (1)
- statins (1)
- stomach (1)
- streptomyces (1)
- sub-Saharan Africa (1)
- subtypes (1)
- sugars (1)
- susceptibility (1)
- synapses (1)
- synaptic plasticity (1)
- tMCAO (1)
- tandem mass-spectrometry (1)
- targets (1)
- testosterone production (1)
- tetrafluoropropene (1)
- therapeutic potential (1)
- thyroid hormone (1)
- tissue (1)
- tolbutamide substrate (1)
- toxicity testing (1)
- toxicocinética (1)
- toxicokinetics (1)
- toxicology (1)
- trans-1 (1)
- trans-Golgi network (1)
- transgenic animals (1)
- triazolotriazine derivatives (1)
- trifluoropropionic acid (1)
- tuber (1)
- tumour (1)
- tyrosine phosphatase (1)
- ultrastructure (1)
- urea (1)
- variocosities (1)
- vav2 (1)
- vitamin-D-receptor (1)
- volume overload (1)
- warfarin polymorphisms (1)
- weight of evidence (1)
- yellow fluorescent protein (1)
- µ-Opioid receptor (1)
- β-adrenergic receptors (1)
- β1-adrenoceptor/β1-adrenergic receptor (1)
- βAR (1)
- γ-Aminobutyric acid (GABA) (1)
Institute
- Institut für Pharmakologie und Toxikologie (302) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (1)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (1)
- Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V. (1)
- Max Delbrück Center for Molecular Medicine (1)
- Max-Delbrück-Center für molekulare Medizin, Berlin (1)
- Pharmakologie, Universität Bonn (1)
- Pharmazie, Universität Mailand (1)
Diabetes, a chronic group of medical disorders characterized byhyperglycemia, has become a global pandemic. Some hormones may influence the course and outcome of diabetes, especially if they potentiate the formation of reactive oxygen species (ROS). There is a close relationship between thyroid disorders and diabetes. The main objective of this investigation was to find out whether peripheral blood mononuclear cells (PBMCs) are more prone to DNA damage by triiodothyronine (T\(_3\)) (0.1, 1 and 10 μM) at various stages of progression through diabetes (obese, prediabetics, and type 2 diabetes mellitus—T2DM persons). In addition, some biochemical parameters of oxidative stress (catalase-CAT, thiobarbituric acid reactive substances—TBARS) and lactate dehydrogenase (LDH) were evaluated. PBMCs from prediabetic and diabetic patients exhibited increased sensitivity for T\(_3\) regarding elevated level of DNA damage, inhibition of catalase, and increase of TBARS and LDH. PBMCs from obese patients reacted in the same manner, except for DNA damage. The results of this study should contribute to a better understanding of the role of thyroid hormones in the progression of T2DM.
In the heart the β\(_1\)-adrenergic receptor (AR) and the β\(_2\)-AR, two prototypical G protein-coupled receptors (GPCRs), are both activated by the same hormones, namely adrenaline and noradrenaline. Both receptors couple to stimulatory G\(_s\) proteins, mediate an increase in cyclic adenosine monophosphate (cAMP) and influence the contractility and frequency of the heart upon stimulation. However, activation of the β\(_1\)-AR, not the β\(_2\)-AR, lead to other additional effects, such as changes in gene transcription resulting in cardiac hypertrophy, leading to speculations on how distinct effects can arise from receptors coupled to the same downstream signaling pathway.
In this thesis the question of whether this distinct behavior may originate from a differential localization of these two receptors in adult cardiomyocytes is addressed. Therefore, fluorescence spectroscopy tools are developed and implemented in order to elucidate the presence and dynamics of these endogenous receptors at the outer plasma membrane as well as on the T-tubular network of intact adult cardiomyocytes. This allows the visualization of confined localization and diffusion of the β\(_2\)-AR to the T-tubular network at endogenous expression. In contrast, the β\(_1\)-AR is found diffusing at both the outer plasma membrane and the T-tubules. Upon overexpression of the β\(_2\)-AR in adult transgenic cardiomyocytes, the receptors experience a loss of this compartmentalization and are also found at the cell surface. These data suggest that distinct signaling and functional effects can be controlled by specific cell surface targeting of the receptor subtypes.
The tools at the basis of this thesis work are a fluorescent adrenergic antagonist in combination of fluorescence fluctuation spectroscopy to monitor the localization and dynamics of the lowly expressed adrenergic receptors. Along the way to optimizing these approaches, I worked on combining widefield and confocal imaging in one setup, as well as implementing a stable autofocus mechanism using electrically tunable lenses.
Dilated cardiomyopathy (DCM) is a common cause of heart failure (HF) and is of familial origin in 20–40% of cases. Genetic testing by next-generation sequencing (NGS) has yielded a definite diagnosis in many cases; however, some remain elusive. In this study, we used a combination of NGS, human-induced pluripotent-stem-cell-derived cardiomyocytes (iPSC-CMs) and nanopore long-read sequencing to identify the causal variant in a multi-generational pedigree of DCM. A four-generation family with familial DCM was investigated. Next-generation sequencing (NGS) was performed on 22 family members. Skin biopsies from two affected family members were used to generate iPSCs, which were then differentiated into iPSC-CMs. Short-read RNA sequencing was used for the evaluation of the target gene expression, and long-read RNA nanopore sequencing was used to evaluate the relevance of the splice variants. The pedigree suggested a highly penetrant, autosomal dominant mode of inheritance. The phenotype of the family was suggestive of laminopathy, but previous genetic testing using both Sanger and panel sequencing only yielded conflicting evidence for LMNA p.R644C (rs142000963), which was not fully segregated. By re-sequencing four additional affected family members, further non-coding LMNA variants could be detected: rs149339264, rs199686967, rs201379016, and rs794728589. To explore the roles of these variants, iPSC-CMs were generated. RNA sequencing showed the LMNA expression levels to be significantly lower in the iPSC-CMs of the LMNA variant carriers. We demonstrated a dysregulated sarcomeric structure and altered calcium homeostasis in the iPSC-CMs of the LMNA variant carriers. Using targeted nanopore long-read sequencing, we revealed the biological significance of the variant c.356+1G>A, which generates a novel 5′ splice site in exon 1 of the cardiac isomer of LMNA, causing a nonsense mRNA product with almost complete RNA decay and haploinsufficiency. Using novel molecular analysis and nanopore technology, we demonstrated the pathogenesis of the rs794728589 (c.356+1G>A) splice variant in LMNA. This study highlights the importance of precise diagnostics in the clinical management and workup of cardiomyopathies.
Cancer and heart disease are leading causes of morbidity and mortality worldwide. These diseases have common risk factors, common molecular signaling pathways that are central to their pathogenesis, and even some disease phenotypes that are interdependent. Thus, a detailed understanding of common regulators is critical for the development of new and synergistic therapeutic strategies. The Raf kinase inhibitory protein (RKIP) is a regulator of the cellular kinome that functions to maintain cellular robustness and prevent the progression of diseases including heart disease and cancer. Two of the key signaling pathways controlled by RKIP are the β-adrenergic receptor (βAR) signaling to protein kinase A (PKA), particularly in the heart, and the MAP kinase cascade Raf/MEK/ERK1/2 that regulates multiple diseases. The goal of this review is to discuss how we can leverage RKIP to suppress cancer without incurring deleterious effects on the heart. Specifically, we discuss: (1) How RKIP functions to either suppress or activate βAR (PKA) and ERK1/2 signaling; (2) How we can prevent cancer-promoting kinase signaling while at the same time avoiding cardiotoxicity.
Ischemic disorders are the leading cause of death worldwide. The extracellular signal-regulated kinases 1 and 2 (ERK1/2) are thought to affect the outcome of ischemic stroke. However, it is under debate whether activation or inhibition of ERK1/2 is beneficial. In this study, we report that the ubiquitous overexpression of wild-type ERK2 in mice (ERK2\(^{wt}\)) is detrimental after transient occlusion of the middle cerebral artery (tMCAO), as it led to a massive increase in infarct volume and neurological deficits by increasing blood–brain barrier (BBB) leakiness, inflammation, and the number of apoptotic neurons. To compare ERK1/2 activation and inhibition side-by-side, we also used mice with ubiquitous overexpression of the Raf-kinase inhibitor protein (RKIP\(^{wt}\)) and its phosphorylation-deficient mutant RKIP\(^{S153A}\), known inhibitors of the ERK1/2 signaling cascade. RKIP\(^{wt}\) and RKIP\(^{S153A}\) attenuated ischemia-induced damages, in particular via anti-inflammatory signaling. Taken together, our data suggest that stimulation of the Raf/MEK/ERK1/2-cascade is severely detrimental and its inhibition is rather protective. Thus, a tight control of the ERK1/2 signaling is essential for the outcome in response to ischemic stroke.
G protein-coupled receptors (GPCRs) constitute the largest class of membrane proteins, and are the master components that translate extracellular stimulus into intracellular signaling, which in turn modulates key physiological and pathophysiological processes. Research within the last three decades suggests that many GPCRs can form complexes with each other via mechanisms that are yet unexplored. Despite a number of functional evidence in favor of GPCR dimers and oligomers, the existence of such complexes remains controversial, as different methods suggest diverse quaternary organizations for individual receptors. Among various methods, high resolution fluorescence microscopy and imagebased fluorescence spectroscopy are state-of-the-art tools to quantify membrane protein oligomerization with high precision. This thesis work describes the use of single molecule fluorescence microscopy and implementation of two confocal microscopy based fluorescence fluctuation spectroscopy based methods for characterizing the quaternary organization of two class A GPCRs that are important clinical targets: the C-X-C type chemokine receptor 4 (CXCR4) and 7 (CXCR7), or recently named as the atypical chemokine receptor 3 (ACKR3). The first part of the results describe that CXCR4 protomers are mainly organized as monomeric entities that can form transient dimers at very low expression levels allowing single molecule resolution. The second part describes the establishment and use of spatial and temporal brightness methods that are based on fluorescence fluctuation spectroscopy. Results from this part suggests that ACKR3 forms clusters and surface localized monomers, while CXCR4 forms increasing amount of dimers as a function of receptor density in cells. Moreover, CXCR4 dimerization can be modulated by its ligands as well as receptor conformations in distinct manners. Further results suggest that antagonists of CXCR4 display distinct binding modes, and the binding mode influences the oligomerization and the basal activity of the receptor: While the ligands that bind to a “minor” subpocket suppress both dimerization and constitutive activity, ligands that bind to a distinct, “major” subpocket only act as neutral antagonists on the receptor, and do not modulate neither the quaternary organization nor the basal signaling of CXCR4. Together, these results link CXCR4 dimerization to its density and to its activity, which may represent a new strategy to target CXCR4.
The A\(_{2A}\) adenosine receptor (A\(_{2A}\)AR) is one of the four subtypes activated by nucleoside adenosine, and the molecules able to selectively counteract its action are attractive tools for neurodegenerative disorders. In order to find novel A\(_{2A}\)AR ligands, two series of compounds based on purine and triazolotriazine scaffolds were synthesized and tested at ARs. Compound 13 was also tested in an in vitro model of neuroinflammation. Some compounds were found to possess high affinity for A\(_{2A}\)AR, and it was observed that compound 13 exerted anti-inflammatory properties in microglial cells. Molecular modeling studies results were in good agreement with the binding affinity data and underlined that triazolotriazine and purine scaffolds are interchangeable only when 5- and 2-positions of the triazolotriazine moiety (corresponding to the purine 2- and 8-positions) are substituted.
Application of adverse outcome pathways (AOP) and integration of quantitative in vitro to in vivo extrapolation (QIVIVE) may support the paradigm shift in toxicity testing to move from apical endpoints in test animals to more mechanism-based in vitro assays. Here, we developed an AOP of proximal tubule injury linking a molecular initiating event (MIE) to a cascade of key events (KEs) leading to lysosomal overload and ultimately to cell death. This AOP was used as a case study to adopt the AOP concept for systemic toxicity testing and risk assessment based on in vitro data. In this AOP, nephrotoxicity is thought to result from receptor-mediated endocytosis (MIE) of the chemical stressor, disturbance of lysosomal function (KE1), and lysosomal disruption (KE2) associated with release of reactive oxygen species and cytotoxic lysosomal enzymes that induce cell death (KE3). Based on this mechanistic framework, in vitro readouts reflecting each KE were identified. Utilizing polymyxin antibiotics as chemical stressors for this AOP, the dose-response for each in vitro endpoint was recorded in proximal tubule cells from rat (NRK-52E) and human (RPTEC/TERT1) in order to (1) experimentally support the sequence of key events (KEs), to (2) establish quantitative relationships between KEs as a basis for prediction of downstream KEs based on in vitro data reflecting early KEs and to (3) derive suitable in vitro points of departure for human risk assessment. Time-resolved analysis was used to support the temporal sequence of events within this AOP. Quantitative response-response relationships between KEs established from in vitro data on polymyxin B were successfully used to predict in vitro toxicity of other polymyxin derivatives. Finally, a physiologically based kinetic (PBK) model was utilized to transform in vitro effect concentrations to a human equivalent dose for polymyxin B. The predicted in vivo effective doses were in the range of therapeutic doses known to be associated with a risk for nephrotoxicity. Taken together, these data provide proof-of-concept for the feasibility of in vitro based risk assessment through integration of mechanistic endpoints and reverse toxicokinetic modelling.
Proteolytic cleavage of the extracellular domain affects signaling of parathyroid hormone 1 receptor
(2022)
Parathyroid hormone 1 receptor (PTH1R) is a member of the class B family of G protein-coupled receptors, which are characterized by a large extracellular domain required for ligand binding. We have previously shown that the extracellular domain of PTH1R is subject to metalloproteinase cleavage in vivo that is regulated by ligand-induced receptor trafficking and leads to impaired stability of PTH1R. In this work, we localize the cleavage site in the first loop of the extracellular domain using amino-terminal protein sequencing of purified receptor and by mutagenesis studies. We further show, that a receptor mutant not susceptible to proteolytic cleavage exhibits reduced signaling to G\(_s\) and increased activation of G\(_q\) compared to wild-type PTH1R. These findings indicate that the extracellular domain modulates PTH1R signaling specificity, and that its cleavage affects receptor signaling.
Analysis of the Frequency of Kidney Toxicity in Preclinical Safety Studies using the eTOX Database
(2022)
This research aimed to obtain reliable data on the frequency of different
types of renal toxicity findings in 28-day oral gavage studies in Wistar rats, their
consistency across species and study duration, as well as the correlation between histopathological endpoints and routinely used clinical chemistry parameters indicative of kidney injury. Analysis of renal histopathological findings was
carried out through extraction of information from the IMI eTOX database.
Spontaneous renal histopathological findings in 28-day oral gavage studies in control Wistar rats and beagle dogs confirmed tubular basophilia and renal
dilation as the most frequent incidental findings in controls, whereas necrosis
and glomerulosclerosis were not identified at all or only rarely as a background
lesion.
Histopathological evidence of necrosis and glomerulosclerosis was associated with changes in clinical chemistry parameters in 28-day oral gavage
Wistar rat studies. Necrosis was frequently accompanied by a statistically significant rise in serum creatinine and serum urea, whereas serum albumin was
frequently found to decrease statistically significantly in treatment groups in
which necrosis was recorded. In contrast to necrosis, glomerulosclerosis was
not associated with statistically significant changes in serum creatinine and urea
in any of the 28-day oral gavage Wistar rat treatment groups, but appears to be
best reflected by a pattern of statistically significantly lowered serum albumin
and serum protein together with a statistically significant increase in serum cholesterol. As might have been expected based on the high background incidences
of tubular basophilia and dilation, no consistent changes in any of the clinical
chemistry parameters were evident in animals in which renal lesions were confined to renal tubular basophilia or dilation. In summary, the routinely provided
clinical chemistry parameters are rather insensitive - novel kidney biomarkers
such as Cystatin C, β-trace protein and Kidney injury molecule 1 should further
be evaluated and integrated into routine preclinical and clinical practice. However, evaluation of clinical chemistry data was limited by the lack of individual
animal data. Even though an extensive amount of preclinical studies is accessible
through the eTOX database, comparison of consistency across time was limited
by the limited number of shorter- and longer term studies conducted with the
compounds identified as causing renal histopathological changes within a 28-
day study in rats. A high consistency across time for both treatment-related tubular basophilia and treatment-related dilation cannot be confirmed for either of
the two effects as these two findings were both induced only rarely in studies
over a different treatment-duration other than 28 days after administration of the
compounds which provoked the respective effect in a 28-day study. For the
finding of necrosis consistency across time was low with the exception of
“AZ_GGA_200002321”, in which renal papillary necrosis was identified consistently throughout different treatment durations (2, 4, 26, 104 weeks). No shorter and longer-term studies were available for the compounds identified as causing
glomerulosclerosis within a 28-day study in rats.
No consistent findings of the selected histopathological endpoints were
identified in any of the corresponding 28-day oral gavage beagle dog studies
after treatment with the identical compounds, which caused the respective effect after 28-day treatment in rats. However, in the overwhelming majority of
cases, beagle dogs were administered lower doses in these studies in comparison to the corresponding 28-day Wistar rat studies.
Searching the eTOX database yielded no 28-day oral gavage studies in
Wistar and Wistar Han rats in which accumulation of hyaline droplets, tubular
atrophy or hyperplasia was recorded. Only one 28-day oral gavage Wistar rat
study was identified with the histopathological result of neutrophilic inflammation. Consequently, evaluation of these four renal findings in relation to clinical
chemistry parameters and consistency across time and species cannot be
made.
In summary, this work contributes knowledge through mining and evaluating the eTOX database on a variety of specific renal endpoints that frequently
occur after administration of trial substances in 28-day oral gavage studies in
Wistar rats in the field of preclinical toxicity with specific focus on their frequency relation to background findings, as well as consistency across time and species. Targeted statistical evaluation of in vivo data within joint research ventures
such as the eTOX project, presents an enormous opportunity for an innovative
future way of aiding preclinical research towards a more efficient research in the
preclinical stage of drug development. This could be achieved through the augmentation of methodological strategies and possibly novel software tools in order to predict in vivo toxicology of new molecular entities by means of information that is already available before early stages of the drug development
pipeline begin.